Johnson & Johnson News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

18.11.24	CHMP Recommends Approval Of Lazcluze + Rybrevant In EU For EGFR-mutated Advanced NSCLC (RTTNews)
14.11.24	JNJ's Phase 2 Study Of Nipocalimab Shows Improvement In Disease Activity In Sjögren's Disease (RTTNews)
08.11.24	Johnson & Johnson Seeks Approval Of Darzalex Faspro In US, Darzalex In EU For Myeloma Treatment (RTTNews)
28.10.24	J&J Reports Positive Results From GRAVITI Study Of Tremfya In SC Induction And Maintenance Therapy (RTTNews)
25.10.24	J&J Phase 3b SPECTREM Study Of Tremfya In Low Body Surface Area Plaque Psoriasis Meets Primary Goal (RTTNews)
15.10.24	Johnson & Johnson Cuts FY24 Earnings View, Lifts Sales Forecast - Update (RTTNews)
15.10.24	Johnson & Johnson Q3 Profit Decreases, But Beats Estimates (RTTNews)
10.10.24	J&J Says TREMFYA Showed Strong Results In Biologic-Naive & Refractory Patients With CD And UC (RTTNews)
10.10.24	J&J Submits For EMA Approval For DARZALEX SC Quadruplet Regimen In Newly Diagnosed Multiple Myeloma (RTTNews)
09.10.24	Johnson & Johnson Buys Privately-held V-Wave; Sees In-process R&D Charge Of Around $600 Mln In Q4 (RTTNews)
04.10.24	JNJ To Terminate Phase 2 Field Study Of Mosnodenvir For Prevention Of Dengue Virus (RTTNews)
02.10.24	JNJ's Erleada Shows Statistically Significant Overall Survival In Metastatic Prostate Cancer (RTTNews)
30.09.24	Johnson & Johnson Expands Roll-out Of TECNIS Odyssey IOL - Quick Facts (RTTNews)
28.09.24	J&J : DARZALEX FASPRO Quadruplet Regimen Improves MRD Negativity In Newly Diagnosed Multiple Myeloma (RTTNews)
28.09.24	J&J : Phase 3 Trial Results Show CARVYKTI Extends Overall Survival In Relapsed Multiple Myeloma (RTTNews)
27.09.24	Johnson & Johnson Says Darzalex Regimens Show Meaningful Responses In Patients With Multiple Myeloma (RTTNews)
27.09.24	Johnson & Johnson Reports New Data From Phase 1b TRIMM-2 Study (RTTNews)
27.09.24	J&J Reports Data From Investigational Phase 1b RedirecTT-1 Study - Quick Facts (RTTNews)
21.09.24	J&J's Subsidiary Red River Talc Files For Chapter 11 Bankruptcy To Resolve Ovarian Cancer Claims (RTTNews)
20.09.24	Janssen-Cilag Reports CHMP Recommendation For Daratumumab - Quick Facts (RTTNews)
20.09.24	FDA Okays J&J's RYBREVANT For Advanced Non-Small Cell Lung Cancer In Combination With Chemotherapy (RTTNews)
16.09.24	Johnson & Johnson Reports Promising Interim Data From Phase 2 SunRISe-4 Study (RTTNews)
15.09.24	J&J's TAR-200 Phase 2b SunRISe-1 Study Shows 84% Complete Response In High-Risk Bladder Cancer (RTTNews)
14.09.24	J&J Announces Promising Phase 1b/2 Data For Amivantamab Combination In Metastatic Colorectal Cancer (RTTNews)
14.09.24	J&J: RYBREVANT + Chemotherapy Shows Strong Benefits And Improved Survival In Phase 3 NSCLC Trial (RTTNews)
12.09.24	Janssen-Cilag Announces First EMA Submission For Nipocalimab - Quick Facts (RTTNews)
12.09.24	J&J's TREMFYA Receives FDA Approval For Moderately To Severely Active Ulcerative Colitis In Adults (RTTNews)
11.09.24	J&J's Dexamethasone Regimen Reduces Infusion Reactions In EGFR-Mutated NSCLC Patients On RYBREVANT (RTTNews)
09.09.24	J&J : Phase 3 Data Show RYBREVANT + LAZCLUZE Outperforms Osimertinib In Non-small Cell Lung Cancer (RTTNews)
01.09.24	Weekly Biotech Buzz: BMRN Cuts Jobs, FDA Approves New Mpox Vaccine, MRK Halts 2 Keytruda Studies (RTTNews)
29.08.24	J&J Files For FDA Approval Of Nipocalimab To Treat Generalized Myasthenia Gravis (RTTNews)
25.08.24	Weekly Biotech Buzz: AADI Trims R&D Jobs, JNJ Loosens Purse Strings, FDA Snubs REGN's Myeloma Drug (RTTNews)
23.08.24	Janssen-Cilag's Balversa Gets EC Approval For Metastatic Urothelial Carcinoma (RTTNews)
20.08.24	Johnson & Johnson To Acquire V-Wave For Initial Payment Of $600 Mln (RTTNews)
20.08.24	Johnson & Johnson's Chemotherapy-free Lung Cancer Treatment Rybrevant Plus Lazcluze Gets FDA Nod (RTTNews)
31.07.24	Johnson & Johnson : FDA Approves Darzalex Faspro Combination For Multiple Myeloma (RTTNews)
26.07.24	J&J: CHMP Recommends RYBREVANT With Chemo To Treat Advanced EGFR-mutated NSCLC (RTTNews)
26.07.24	Johnson & Johnson's Yuvanci Gets Positive CHMP Opinion In Europe For Pulmonary Arterial Hypertension (RTTNews)
22.07.24	Johnson & Johnson Seeks FDA Approval For SPRAVATO Nasal Spray For Treatment-Resistant Depression (RTTNews)
17.07.24	Johnson & Johnson Q2 Adj. EPS Beats View, Cuts FY24 Earnings Forecast (RTTNews)
17.07.24	Johnson & Johnson Q2 Profit Decreases, But Beats Estimates (RTTNews)
17.07.24	ORIC Enters Into Clinical Trial Collaboration And Supply Agreements With Bayer and J&J; Stock Up (RTTNews)
03.07.24	Johnson & Johnson Announces Health Canada NOC For RYBREVANT Combination - Quick Facts (RTTNews)
02.07.24	J&J Reports Positive Data From Phase 3 CARTITUDE-4 Study Of Carvykti In Multiple Myeloma (RTTNews)
01.07.24	Sandoz To Commercialize Samsung Bioepis' FDA Approved Biosimilar Pyzchiva In US (RTTNews)
28.06.24	J&J: Rybrevant In Combination Gets Approval In Europe For First-Line Treatment Of NSCLC (RTTNews)
28.06.24	Janssen-Cilag Says CHMP Recommended Balversa For Urothelial Carcinoma (RTTNews)
21.06.24	Johnson & Johnson Seeks FDA Approval For Tremfya For Moderate To Severe Crohn's Disease (RTTNews)
20.06.24	Johnson & Johnson: TREMFYA Phase 3 Study Meets Primary And Secondary Endpoints (RTTNews)
17.06.24	J&J Submits BLA For Subcutaneous Amivantamab Combination In EGFR-mutated NSCLC Patients (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

17:58		Börse Europa in Grün: STOXX 50 zeigt sich zum Ende des Donnerstagshandels fester
17:58		Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen
17:58		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
17:58		SMI aktuell: SMI präsentiert sich letztendlich fester
17:58		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
17:58		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
17:58		SLI aktuell: Anleger lassen SLI letztendlich steigen

17:58

Börse Europa in Grün: STOXX 50 zeigt sich zum Ende des Donnerstagshandels fester

17:58

Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen

17:58

Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX

17:58

SMI aktuell: SMI präsentiert sich letztendlich fester

17:58

Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus

17:58

Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone